ABSTRACT. To develop a live vaccine for equine herpesvirus type 1 (EHV-1), two EHV-1 mutants containing no heterogeneous DNA, ∆gI and ∆gE, were constructed with deletions in the open reading frame of either glycoprotein I (gI) or E (gE), respectively. In equine cell culture, deletion mutants formed smaller plaques than the parental and revertant viruses, but the one-step growth patterns of the deletion mutants and the parental strain were approximately the same. These results suggest that both gI and gE contribute to the ability of EHV-1 to spread directly from cell-to-cell, but that these glycoproteins are not required for viral growth in vitro. Mice and hamsters inoculated intranasally with these mutants showed no clinical signs, and continued to gain weight, whereas those inoculated with the parental virus exhibited a reduction in mean body weight. Furthermore, nervous manifestations were observed in hamsters inoculated with the parental virus. These results suggest that gI and gE have an important role in EHV-1 virulence including neurovirulence in experimental animal models. On the other hand, serum neutralizing antibodies were detected in mice immunized with ∆gI or ∆gE at two weeks after inoculation. Following challenge with the parental virus, ∆gI-or ∆gE-immunized mice were able to clear parental virus from their lungs faster than mock-immunized mice. These results suggest that the EHV-1 mutants defective in gI and in gE are attenuated but have ability to elicit immune responses in inoculated mice that contribute to virus clearance. KEY WORDS: attenuated live vaccine, EHV-1, gE, gI.
Equine herpesvirus type 1 (EHV-1), a member of the subfamily Alphaherpesvirinae, is a major causative agent of respiratory disease in horses [2] . EHV-1 can also cause abortion and neurological disease, which have a great economic impact on the horse industry. In Japan, the respiratory disease among racehorses due to EHV-1 infection occurs during the winter of each year [28] . To prevent diseases caused by EHV-1 infection, an inactivated vaccine has been used for susceptible populations in Japan but with a limited efficacy. Inactivated vaccines are generally known to be weak inducers of cell-mediated immunity that is responsible for controlling EHV-1 infection [3] . In contrast, modified live vaccines usually induce adequate humoral and cellular immune responses in inoculated animals [31] .
A live vaccine against EHV-1 should be completely safe, since it would be inoculated into racehorses, which are delicate animals to maintain in excellent condition for races. To assess EHV-1 virulence, mice have been used as experimental animals, as well as natural equine hosts [5] . Recently, the hamster model has shown to be useful for studying EHV-1 neurovirulence [35] . Therefore, the genetic basis responsible for virulence of EHV-1 has been investigated for the purpose of developing an effective live attenuated vaccine by using these animal models.
The genome of EHV-1 is approximately 150-kb, and is composed of two unique segments, U L and U S , each bound by inverted repeat sequences IR L /TR L and IR S /TR S , respectively [9, 16, 38, 45] . DNA sequence analysis of the Ab4 EHV-1 genome revealed the presence of 76 genes [44] . Genes 33 (gB), 52 (gM), 67 (IR6), and 71 (EUS4) have been shown to be associated with EHV-1 virulence in mice [24, 32, 34] . Gene 38, which encodes viral thymidine kinase (TK), was confirmed to be associated with virulence of EHV-1 in the natural host [11, 40] . However, an EHV-1 TK-deficient mutant still exhibited mild virulence for specific pathogen-free (SPF) foals [40] . The EHV-1 strain Kentucky A (KyA) lacks at least six genes (genes 1, 2, 17, 73, 74, and 75) [13, 27, 47] by a long passage history in vivo in Syrian hamster and in vitro in mouse L-M fibroblast tissue culture [4, 33, 36] , and was shown to be attenuated in young horses and mice [10, 26] . Two glycoproteins, gI and gE, which are encoded by genes 73 and 74, respectively, and defective in the KyA strain, have been implicated as virulence genes in other Alphaherpesvirinae including herpes simplex virus type 1 (HSV-1) [12] , pseudorabies virus (PRV) [21] , bovine herpesvirus type 1 (BHV-1) [20] , and feline herpesvirus type 1 (FHV-1) [22, 43] . In fact, BHV-1 and PRV mutants that are gE deficient have been used as live attenuated vaccines in the field [23, 42] .
To confirm the association of gI and gE genes with EHV-1 virulence, we constructed an EHV-1 recombinant with deletions in the gI and gE genes (∆gE∆gI-lacZ) in a previous study [25] . The ∆gE∆gI-lacZ was avirulent in colostrumdeprived foals when inoculated intranasally (i.n.), suggesting that the gI and/or gE genes of EHV-1 were associated with EHV-1 virulence in horses. However, the ∆gE∆gI-lacZ induced only partial protection in inoculated foals against manifestation of respiratory symptoms after challenge infection with the parental virus, suggesting that gI and/or gE of EHV-1 would have an important role in induction of protective immunity in horses [25] . Glycoproteins I and E have been shown to form a noncovalently linked het-ero-oligomeric complex in other alphaherpesviruses, HSV-1 [8, 19] , PRV [50] , BHV-1 [7, 46] , FHV-1 [29, 30] , and varicella-zoster virus [48] , and the gI-gE complex is implicated in virus spread [12, 18, 29, 37, 49] . However, each of the gI and gE of HSV-1 has shown to be able to induce protective immunity in mice against lethal HSV-1 infection [15] . Therefore, it is assumable that immunogenicity of EHV-1 might be affected by the presence or absence of each glycoprotein, gI or gE, although whether gI and gE of EHV-1 form a complex is still unknown. Recently, the important role of gI gene in EHV-1 virulence in mice was suggested by the study using KyA mutants, in which the insertion of genes 73 (gI), 74 (gE), and 75 (putative 10 kDa protein 75) into avirulent KyA strain restored the virulence, but the insertion of genes 74 and 75 did not affect the KyA avirulence [14] . However, associations of gE gene with EHV-1 virulence and of gI and gE genes with EHV-1 immunogenicity are remained to be clear.
Furthermore, the mutant contained heterogeneous transgenic DNA (E. coli lacZ gene) is not suitable as a vaccine strain in Japan, since a strict safety regulation for the practical use of products made by genetic recombination exists in Japan. In this study, therefore, we constructed EHV-1 mutants defective in gI (∆gI) and in gE (∆gE), which do not contain heterogeneous DNA, and examined for growth properties, and virulence and immunogenicity of the mutants in vitro and in experimental animal models, respectively, in order to evaluate whether the mutants possess suitable feature for live vaccine candidate strains.
MATERIALS AND METHODS

Viruses and cells:
All recombinants were constructed from EHV-1 strain 89c25p, which is a plaque-purified strain of a low passaged field strain, 89c25. The 89c25 strain was isolated from a racehorse during an epizootic of EHV-1 respiratory infection in 1989 [28] . Fetal horse kidney cells (FHK, within the seventh passage from primary culture) were used throughout the study except for mutant virus selection, for which RK13 cells (an established cell line of rabbit kidney) were used. In addition, MDBK cells (an established cell line of bovine kidney) were used for serum neutralization (SN) test. Cells were grown in Eagle's minimum essential medium (EMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics (growth medium).
Plasmids for generating mutant viruses: The plasmid pSma-Bam which contained a 5.8-kb SmaI/BamHI fragment of 89c25p Us region was constructed previously (Fig. 1A II (Fig. 1A V) . Secondly, plasmids that can be used to remove the lacZ gene from lacZ positive mutants were prepared. The DNA fragment of pSma-Bam was amplified by long and accurate (LA-) PCR with primer sets, pr-gI5' and pr-gI3', or pr-gE5' and pr-gE3' ( Fig. 2A and B). These primers have an Eam1104 restriction sequence at the 5' terminus, and the cleavage site by digestion with type IIs RE Eam1104 (Stratagene, CA), which cuts 3' of its restriction sequence, extends one nucleotide on the upper strand in the 3' direction and four nucleotides on the lower strand in the 5' direction. Each of the LA-PCR products was digested with Eam1104 and then self-ligated ( Fig.  2 ). Newly generated plasmids were designated as p∆gI and p∆gE ( Fig. 1B II 
and III). The p∆gI, containing a new
BssHII recognition site at the junction site ( Fig. 2A) , lacked 1,117 of 1,275 bp of the EHV-1 gI sequence. The p∆gE, containing a new BglII recognition site at the junction site ( Fig. 2B ), lacked 1,149 of 1,653 bp of the EHV-1 gE sequence. Newly generated RE sites were confirmed by RE digestions.
Homologous recombination and recombinant screening: Homologous recombination and recombinant screening strategies used in this study were described previously [25] . Briefly, linearized donor plasmids were transfected into FHK cells infected with various EHV-1 strains by electroporation using gene transfer equipment (Gene Pulser, Bio-Rad Laboratories, CA). Transfected cells were grown in 6-well culture plates at 37°C in a 5% CO 2 atmosphere and harvested with a cell scraper at 4 days when cytopathic effect (CPE) appeared. Mutant virus stocks were obtained by disrupting cells by three freeze-thaw cycles and clearing them by centrifugation. Mutants containing lacZ gene were selected by blue plaque cloning on RK13 cells in the presence of 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal; Takara Biomedicals, Japan), while those not containing lacZ gene were selected by colorless plaque cloning on RK13 cells under the same conditions.
Construction of gI and gE deletion mutants and their revertants:
For generation of the lacZ recombinant mutants, linearized p∆gI-lacZ or p∆gE-lacZ was transfected into FHK cells infected with the 89c25p strain. Purification of EHV-1 mutants was achieved by repeated blue plaque cloning on RK13 cells in the presence of X-gal and resulting mutants were designated as ∆gI-lacZ and ∆gE-lacZ. To obtain EHV-1 mutants without a lacZ cassette, linearized p∆gI and p∆gE were transfected into FHK cells infected with the ∆gI-lacZ and ∆gE-lacZ strains, respectively. By repeated colorless plaque cloning on RK13 cells in the presence of X-gal, EHV-1 deletion mutants void of the lacZ cassette were obtained, and designated as ∆gI and ∆gE. Construction and purification of revertant viruses of ∆gI and ∆gE, gI-rev and gE-rev, were achieved by transfecting pSma-Bam DNA into FHK cells infected with ∆gI and ∆gE strains, respectively and by selecting the clones, which produced larger plaques than those of deletion mutants.
PCR and DNA sequencing: PCR and DNA sequencing were conducted to identify the deletion of gI or gE sequence and the presence or absence of lacZ gene sequence, as well as to confirm the stability of the EHV-1 sequences at ligation sites (SmaI and BamHI sites) within the genome of each mutant virus with primers used previously; gI up/down, gE up/down, lacZ 3 up/down, Sma sequence up/down, and Bam sequence up/down [25] . Furthermore, the PCR product amplified from ∆gI or ∆gE using each primer set, which amplified the entire gI gene or gE gene, was cloned using a TA cloning kit (Invitrogen, CA), and sequenced with universal primers. To confirm the sequence of gI and gE genes in gI-rev and gE-rev, LA-PCR was conducted to gI-rev and gE-rev DNAs with Sma sequence up and Bam sequence down primers [25] which amplify a 5.8-kb SmaI/BamHI fragment of EHV-1 and resulting amplicons were directsequenced with twenty four primers which enable to read entire sequences from the upstream region of gI gene to the downstream region of gE gene from both direction. Sequence reactions were carried out by cycle sequencing reactions (Applied Biosystems, CA), and analyzed on an Applied Biosystems DNA sequencer (Model 310).
Southern blot hybridization: Digoxigenin (DIG)-labeled gI (nt 133,174 to 133,768) and gE (nt 135,072 to 135,581) fragments amplified from 89c25p DNA by using primer sets, gI up/down and gE up/down [25] , respectively, were used as probes for hybridization. Hybridization assays and chemiluminescent detection of the probed fragment were performed as described previously [25] .
Plaque size measurement: FHK monolayers in 6-well culture plates were inoculated with 10 to 15 plaque-forming unit (pfu) of each virus per well. Following 1-hr adsorption, cells were overlaid with EMEM containing 1% methylcellulose (overlay medium) and cultured for 5 days. Cells were then fixed and stained with crystal violet solution (0.2% crystal violet, 10% methanol, 10% formalin, and 2% sodium acetate). To determine the average plaque size, 100 randomly chosen plaques were measured using a Lane & Spot Analyzer ver. 6 (ATTO Corporation, Japan). Welch's or Student's t-test was employed to compare the mean plaque sizes of viruses examined.
Time course of viral growth: Monolayers of FHK cells cultured in 25-cm 2 flasks were inoculated with virus samples at a multiplicity of infection of 10 pfu per cell. After 1-hr adsorption, cells were washed two times with EMEM and incubated at 37°C in 5 ml/flask of growth medium. At 0-, 3, 6-, 9-, 12-, 18-, 24-, 36-, and 48-hr post-infection (p.i.), flasks were stored at -80°C. Following three freeze-thaw cycles and centrifugation, the resulting supernatants were titrated for viral infectivity. FHK cells inoculated with 10-fold dilution of samples were overlaid with overlay medium and cultured for 3 days. Cells were then fixed and stained with crystal violet solution.
Animals: Three-or four-week-old specific pathogen-free (SPF) female BALB/c mice and three-week-old SPF male Syrian hamsters (Japan SLC Inc., Japan) were used in this study. All experimental procedures were approved by the Animal Care Committees of Equine Research Institute and Gifu University.
Virulence of EHV-1 strains in mice and hamsters: Mice (four-week-old) and hamsters were divided into groups of ten and four animals, respectively, and inoculated i.n. under anesthesia by isoflurane inhalation and ketamine administration, respectively, with 25 to 50 µl of 10 6 pfu of each virus. Similarly, each group of control mice and hamsters was inoculated with EMEM. Body weights of individual animals were recorded daily. On days 4 and 7 p.i., five mice of each group were euthanized and lungs were collected for virus isolation.
Immunogenicity and protective efficacy of the mutant viruses in mice: Three immunized groups (∆gI-, ∆gE-, or mock-immunized: n=20) were used in this experiment.
Three-week-old mice were immunized i.n. with 25 to 50 µl of 10 6 pfu of each virus or 25 µl of EMEM. Blood samples were collected by retrobulbar venipuncture 2 weeks after immunization and pooled sera of individual groups were used for SN test. Three weeks after immunization, mice were challenged i.n. with 10 6 pfu of EHV-1 89c25p strain. Also, a negative control group consisting of unimmunized six-week-old mice (n=9) was inoculated i.n. with EMEM. Body weights of individual mice were recorded daily. Lungs for virus isolation and sera for SN test were collected from five euthanized mice of each group on days 1, 3, 5, and 7 post-challenge.
Virus isolation: The Lungs were removed aseptically from the mice and weighed. A 10% w/v suspension of each sample was homogenised with EMEM containing 2% FBS and centrifuged at 2,000 × g for 10-min to remove cell debris. The supernatant was titrated on monolayers of FHK cells as described in Time course of viral growth section.
SN test:
Pooled sera collected from each group were tested for neutralizing antibody. Sera diluted with EMEM (1:2.5) were inactivated at 56°C for 30-min and mixed with equal volumes of EMEM with or without 20% guinea pig complement to make initial dilutions (1:5). Serial two-fold diluted sera were mixed with an equal volume of virus antigen (89c25p) (100 pfu per 100 µl) and incubated at 37°C for 1-hr in the presence or absence of 10% complement. Samples (50 µl/well) were then inoculated onto monolayers of MDBK cells in 24-well plates (4 wells per dilution), and incubated at 37°C in a 5% CO 2 incubator for 3-hr with agitation every 15-min to allow for virus adsorption. Overlay medium (0.5 ml) was then added to each well, and the plates were incubated at 37°C in a 5% CO 2 incubator for 4 days. Antibody titers were expressed as the highest serum dilution that demonstrated a 50% or greater reduction of plaque numbers compared with that of wells inoculated with control virus.
RESULTS
Confirmation of mutant viruses:
Each deletion or insertion of the generated mutants, ∆gI-lacZ, ∆gI, ∆gE-lacZ and ∆gE was confirmed by PCR using primers, gI up/down, gE up/down and lacZ 3 up/down. Sequence analysis of the SmaI and BamHI ligation sites between plasmid DNA and EHV-1 genome revealed no nucleotide changes in the ∆gI and ∆gE genomes compared to the corresponding sequences of the parental 89c25p and the Ab4p strains of EHV-1. Furthermore, designed deletions in ∆gI and ∆gE were confirmed by sequencing of TA-cloned gI segment remaining in ∆gI and of TA-cloned gE segment remaining in ∆gE. Also new RE sites, BssHII in ∆gI and BglII in ∆gE, generated at the deletion sites of ∆gI and ∆gE, respectively, were confirmed. In addition, sequence analysis confirmed that gI and gE genes were properly restored into revertant viruses, gI-rev and gE-rev, respectively. For further confirmation of the deletion of gI and gE genes in the ∆gI and ∆gE genomes, respectively, EHV-1 strains, 89c25p, ∆gI, ∆gE, gI-rev, and gE-rev, were subjected to Southern blot analysis. The gI and gE fragment probes hybridized to a 9.4-kb fragment of ∆gE and ∆gI DNAs, respectively, and to a 10.5-kb BamHI D fragment of 89c25p, gI-rev, and gE-rev DNAs, but failed to hybridized to any fragments of ∆gI and ∆gE DNAs, respectively (data not shown). The result of Southern blot analysis along with the results obtained from PCR and sequence analysis confirmed the deletion of expected sequences in the ∆gI and ∆gE DNAs.
Growth properties of EHV-1 strains in vitro:
To ascertain whether gI and gE influence the direct cell-to-cell spread of EHV-1, FHK cells were infected with 89c25p, ∆gI, ∆gE, gIrev, or gE-rev. The average size of 100 plaques formed 5 days after infection with ∆gI or ∆gE was significantly smaller than plaques formed after infection with 89c25p (Welch's t-test, p<0.01, Table 1 ). In contrast, the plaque size of each revertant virus was statistically similar to that of 89c25p (Student's t-test, P=0.63 for gI-rev; P=0.87 for gErev).
A one-step growth experiment of EHV-1 strains was conducted to examine whether the deletion of either gI or gE gene would affect viral growth in vitro. The virus titers of samples from FHK cells inoculated with 89c25p, ∆gI, and ∆gE reached the peak titers at 36-or 48-hr p.i., and the growth patterns of three strains were quite similar (Fig. 3) .
Virulence of EHV-1 strains in experimental animals:
To compare the virulence of EHV-1 strains in mice, five groups of ten four-week-old mice were inoculated i.n. with EHV-1 strains, 89c25p, ∆gI, ∆gE, gI-rev, and gE-rev, respectively. Both control mice and those inoculated with ∆gI or ∆gE consistently gained weight until day 7 p.i (Fig. 4) . In contrast, groups of mice inoculated with 89c25p, gI-rev, and gE-rev strains experienced similar degree of weight loss from day 2 p.i., and did not regain their pre-infection body weight by day 7 p.i. These findings indicated that the gI and gE deletion mutants of EHV-1 were attenuated and that their revertants derived from ∆gI and ∆gE were pathogenic. Additionally, growth properties of EHV-1 strains in mice were compared by virus isolation from lung tissues of five mice per group collected on days 4 and 7 p.i. Infectious virus was recovered from lungs collected from four 89c25p-and gE-rev-inoculated mice and from two gI-rev-inoculated mice on day 4 p.i. (Table 2 ). In contrast, no infectious virus was recovered from the lungs of ∆gI-or ∆gE-inoculated mice on day 4 p.i. Virus titers of positive samples for isolation were considerably different among individual mice ranging from 1 × 10 2 to 7.5 × 10 3 pfu/g (Table 2 ). Virus was not recovered from lung tissues on day 7 p.i. from any of the groups. These results suggested that deletion of gI or gE resulted in an impaired ability to replicate in vivo.
To assess the neurovirulence of EHV-1 strains, furthermore, hamsters were inoculated i.n. with ∆gI, ∆gE and 89c25p strains. The ∆gI-and ∆gE-inoculated, and control hamsters showed no clinical signs, and continued to gain weight similarly (Fig. 5) . In contrast, all hamsters inoculated with 89c25p exhibited neurological signs, namely restlessness, incoordination, aggressiveness, and lethargy, which started from day 4 to 6 p.i. From day 4 p.i., in concurrence with onset of neurological disorders, 89c25p-inoculated hamsters lost weight, and did not regain their initial weight until day 13 p.i. In addition, one of four hamsters inoculated with 89c25p died on day 7 p.i. The findings suggested that gI and gE are associated with EHV-1 neurovirulence in hamsters.
Immunogenicity of the mutants in mice: To assess the immunogenicity of the mutants, challenge experiments were performed on ∆gI-, ∆gE-, and mock-immunized mice at the age of six weeks by intranasal inoculation with 1 × 10 6 pfu/ mouse of the 89c25p strain. After challenge, infectious virus was recovered from lung tissues of mock-immunized mice until day 5 post-challenge (Table 3) . In contrast, infectious virus was recovered only on day 1 post-challenge from two of five lungs collected from ∆gI-immunized mice, and from one of five lungs collected from ∆gE-immunized mice. Virus titers of positive samples for isolation were considerably different among individual mice ranging from 50 to 9.5 × 10 4 pfu/g ( Table 3 ). The results indicated that the challenge virus was rapidly cleared from the lungs of mice immunized with ∆gI or ∆gE.
To monitor the serological responses of immunized mice, SN test was performed with pooled sera collected at 2 weeks after immunization, and on days 1, 3, 5, and 7 post-challenge. Complement-independent SN antibody against EHV-1 was detected at a titer of 1:5 on day 1 and 1:10 on day 7 post-challenge in ∆gI-immunized mice, but was not detected in ∆gE-and mock-immunized mice. On the other hand, complement-dependent SN antibody against EHV-1 was detected at a titer of 1:5 at 2 weeks after immunization with ∆gI and ∆gE, and 1:10 on day 1 post-challenge (22 days after the immunization), but was not detected in mockimmunized mice up to 5 days post-challenge (Table 4) . Complement-dependent SN antibody titers increased to 1:20 on days 5 and 7 post-challenge in ∆gE-and ∆gI-immunized mice, respectively, and to 1:5 on day 7 in mock immunized mice. These results indicated that immunization of mice with the gI and gE deletion mutants could elicit complement-dependent SN antibody response. However, no clear difference in antibody responses after challenge was observed between mice immunized with each deletion mutant and mock-immunized mice.
DISCUSSION
To elucidate the function of the gI and gE genes of EHV-1 and the possibility of gI and gE deletion mutants of EHV-1 as candidates for vaccine strain, we generated EHV-1 mutants, which lacked almost the entire coding sequence of either gI (∆gI) or gE (∆gE) gene. Since the application of recombinant viruses containing a heterogeneous gene(s) for use as vaccine is strictly regulated in Japan, ∆gI and ∆gE recombinants derived from the 89c25p strain were generated by removing the lacZ gene from ∆gI-lacZ and ∆gE- Fig. 4 . Mean body weights of control mice and those infected with ∆gI, ∆gE, 89c25p, gI-rev, and gE-rev (ten mice per group except for ∆gE infected mice. Three ∆gE-infected mice died at the time of inoculation). Mean body weights of each group are indicated as a percentage of those measured on the day of infection (day 0). Subsequent values for each group represent the mean body weights of ten mice in each group (seven in the ∆gE-infected group) measured until day 4 p.i., and of five mice per group (three in the ∆gE-infected group) from days 5 to 7 p.i., respectively. Error bars represent the standard deviation from the means for each group. lacZ, respectively, and the expected deletion in each recombinant was confirmed by PCR, DNA sequencing, and Southern blot analyses. In p∆gI and p∆gE, a unique RE site was generated at the deletion site to facilitate the insertion of foreign gene(s) for further development of multivalent EHV-1 vector vaccines. The deletion in the ∆gE seems to have no effect on the promoter region of gI gene, whereas the 3' of gI coding sequence remaining in ∆gI was from nt 134,047, position 358 bp upstream from the putative start codon (nt 134,405 to 134,407) of gE gene. Although the gE promoter of EHV-1 has been fully understood, it was reported that the gE promoter of HSV-1 was localized to within 173 bp upstream from the start codon of gE [39] . Therefore, it is assumed that the deletion of gI coding sequence in ∆gI would not affect its gE promoter activity, but the further transcriptional analysis of the gE gene of ∆gI as well as of the gI gene of ∆gE is required.
The ∆gI and ∆gE produced significantly smaller plaques in FHK cells than did the parental and revertant viruses, which suggested that both gI and gE facilitate cell-to-cell spread. Furthermore, the time course of replication of the ∆gI and ∆gE strains in FHK cells was quite similar to that of the parental strain, suggesting that gI and gE of EHV-1 are not involved in the process of virus maturation and release or in virus attachment and penetration. Growth properties of the ∆gI and ∆gE in FHK cells were quite similar to that of the EHV-1 recombinant with deletions in both gI and gE genes observed in the previous study [25] . From these results, however, it is still not clear whether gI and gE of EHV-1 function together as a complex like in other alphaherpesviruses. Therefore further studies are needed to confirm whether gI and gE of EHV-1 do form a gI-gE complex.
The recent study using EHV-1 revertants derived from the KyA laboratory strain reported that gI alone or gI and gE were important virulence factors of EHV-1 in mice, although some other deletions existed in the KyA strain may affect the virulence of the KyA revertants [14] . To assess the function of EHV-1 gI and gE, in this study, single deletion mutants of the EHV-1 wild-type strain 89c25p were examined for their virulence in murine and hamster models. Mice inoculated i.n. with ∆gI or ∆gE did not show any weight loss, whereas mice inoculated with the parental and revertant viruses lost weight from day 2 p.i. until day 3 or 4 p.i., and did not regain their pre-infection body weight by day 7 p.i. Furthermore, on day 4 p.i., infectious virus was recovered from lungs collected from mice inoculated with virulent strains, 89c25p, gI-rev and gE-rev, whereas virus isolation of ∆gI and ∆gE in mouse lungs were negative. These findings suggest that reduced virulence of ∆gI and ∆gE in mice may be due to restricted viral replication in lung tissues of mice. These results are similar to those reported previously where an EHV-1 gene 71-negative mutant, which was avirulent for mice, replicated poorly in respiratory tissues in mice [24] . However, an EHV-1 gene 75-negative mutant, which had almost the same ability to replicate in respiratory tissues of mice as a wild type virus, was slightly attenuated [24] . Therefore, in addition to virus replication levels, other factors may influence EHV-1 virulence in mice. Furthermore, the hamster model was used to assess the association of gI and gE genes in EHV-1 virulence, since the original 89c25 strain has shown to have neurovirulence in hamsters [35] . In the present study, as expected, all hamsters inoculated with the parental EHV-1 strain, 89c25p, showed severe nervous manifestations from day 4 to 6 p.i., and one of four animals died on day 7 p.i. In contrast, hamsters inoculated with ∆gI and ∆gE exhibited no clinical signs, suggesting that both of gI and gE play an important role for EHV-1 neurovirulence in hamsters. The conclusion on the association of gI and gE genes in the EHV-1 virulence in vivo obtained from this study along with the previous study using ∆gE∆gI-lacZ [25] seems to be well coincided with that obtained from the study using the KyA mutants which restored three genes (gI, gE, and 75) and two genes (gE and 75) [14] . However, the deletion of both gI and gE genes from the virulent RacL11 strain of EHV-1 did not reduce clinical signs of disease in infected mice [14] . In contrast to 89c25p strain which was isolated and plaque purified solely in equine cells, RacL11 strain has passaged history in porcine cells and thus some alterations in the genome as compared to the reference Ab4 strain [17] . Since it is assumed that alterations in the RacL11 genome other than gI and gE may compensate for the functions provided by these two glycoproteins, it would be better to use EHV-1 strains with a minimum passaged history in equine culture for assessing the gene functions on EHV-1 virulence. Intranasal immunization with ∆gI and ∆gE evoked complement-dependent SN antibodies in mice by 2 weeks p.i., and virus was cleared from lung tissues more rapidly following challenge in immunized mice than in mock-immunized mice. The results suggested that the gI and gE deletion mutants of EHV-1 could work as EHV-1 immunogen in mice to elicit a complement-dependent SN antibody response to EHV-1 and a potency of EHV-1 clearance. Other than humoral antibodies, it has been reported that cellular immunity contributes to the clearance of EHV-1 strains from infected mouse lungs [1, 6, 41] . Therefore, further studies on cellular immune responses following immunization with mutant viruses are necessary for evaluation of effectivity of live vaccines against EHV-1. On the other hand, changes in mean body weights were not observed among any groups including a control group of mice in the challenge experiment (data not shown), suggesting that the 89c25p strain may be less virulent in six-week-old mice than in four-week-old mice. Since the EHV-1 strains Ab4 and RacL11 were shown to be virulent in six-week-old or elder mice [34, 40] , the 89c25p strain might have less virulence in mice than other EHV-1 strains have.
EHV-1 mutants devoid of gI and gE were avirulent but were immunogenic in experimental animal models. Each mutant contained no heterogeneous DNA and therefore could be considered as candidates for a live vaccine strain. Further studies focusing on the evaluation of ∆gI and ∆gE as live vaccine candidates in horses are under way.
